Auto Stem Cell Transplant for Lymphoma Patients

Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

Study Overview

• Status: Recruiting
• Conditions: Hodgkin Lymphoma; Non-Hodgkin Lymphoma
• Intervention / Treatment: Drug: Etoposide; Drug: BCNU; Drug: AraC; Drug: Melphalan; Procedure: Peripheral blood stem cell transplantation; Biological: G-CSF; Drug: Cyclophosphamide; Radiation: Total Body Irradiation

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Timothy Krepski; Phone Number: 612-273-2800; Email: tkrepsk1@fairview.org

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Recruiting
      • Masonic Cancer Center, University of Minnesota
      • Contact: Timothy Krepski; Phone Number: 612-273-2800; Email: tkrepsk1@fairview.org
      • Principal Investigator: Veronika Bachanova, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 75 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Eligible Diseases

  1. Non-Hodgkin's Lymphoma (NHL)

     • Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification.
     • Patients in partial or complete remission following cell therapy will also be eligible.
     • NHL patients with resistant or refractory lymphoma (no PR following up to three cycles of combination chemotherapy) will not be eligible for transplant in this trial.

     • Lymphoblastic Lymphoma:

       1. All patients will be eligible in second or greater complete remission (CR) or first or subsequent partial remission (PR)
       2. Patients with any high-risk features will be eligible in first complete remission
       3. High risk features include: Stage IV, LDH >2 x upper limit of normal, ≥ 2 extranodal sites

     • Mature B-cell Lymphoma

       1. Follicular Lymphoma and other indolent lymphoma in ≥ second CR2/PR2
       2. Diffuse Large B-Cell Lymphoma: in ≥ CR2 or ≥ PR1; a high intermediate or high IPI (≥ 2 for age-adjusted IPI or ≥3 for IPI) at diagnosis and double-hit or triple-hit lymphoma will be eligible in first CR; transformed lymphoma from FL (or other indolent lymphoma) or chronic lymphocytic leukemia will be eligible if chemosensitive and bone marrow is negative
       3. Mantle Cell Lymphoma: in first or greater CR or PR
       4. Burkitt's/Burkitt's like: all patients except localized lymphoma will be eligible any time after initial therapy (after achievement of first complete remission), or in partial remission if they fail to achieve CR; patients with localized (stage I or Ziegler stage A) will be eligible only if they fail to achieve CR1 or after relapse

     • Mature T-Cell Lymphoma

       1. Chemosensitive T-cell lymphomas including Primary T-cell not otherwise specified angioimmunoblastic, and ALK-positive anaplastic large cell, will be eligible after initial therapy, whether or not CR is achieved.
       2. Mycosis fungoides/Sezary syndrome will be eligible in ≥CR2/PR2

  2. Hodgkin Lymphoma (HL)

     • Patients with histologically proven HL will be eligible for transplantation after failing prior therapy.
     • Patients with resistant disease (initial or at relapse): those who fail to achieve an objective partial response to three cycles of combination non-cross resistant chemotherapy will not be eligible for transplant in this trial.
     • For stage I/II patients treated with primary chemotherapy-radiation, they must have failed (no CR or progression after CR) at least one salvage combination chemotherapy treatment regimen
     • For advanced (stage III/IV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP)

     • Patients with any high-risk features will also be eligible, including those who:

       1. fail to achieve complete remission with initial combination chemotherapy
       2. have bulky disease after initial therapy (chemotherapy or radiation) defined as residual mediastinal mass ≥ 5 cm or other residual mass ≥ 10 cm accompanied by other features of persisting disease (e.g., PET scan positive; high LDH; enlarging on serial x-rays or biopsy positive) will be eligible - if feasible, persistent disease should be proven by biopsy
     • Patients should receive chemotherapy to attempt to achieve CR or minimal disease state for all patients pre-transplantation. The use of up to three cycles of non-cross resistant combination chemotherapy is advised.
     • Residual areas of limited disease should be considered for radiotherapy after and not prior to transplantation.

  3. HIV positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:

     • Are seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period.
     • Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians. For the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor.
     • CD4+ ≥ 50/µL
     • HIV RNA viral load ≤ 100,000 copies per mL on each of samples 4 weeks apart. The most recent level must be within 30 days of enrollment.
• Performance Status: Karnofsky Performance Status ≥ 80% for patients ≥ 16 years of age or Lansky Play Score ≥ 80 for patients < 16 years of age. Note: if poor performance status is due to lymphoma - KPS ≥ 60% or LPS ≥ 60 is acceptable

• Organ Function

  1. No evidence of serious organ dysfunction that is not attributable to tumor including:

  1. Hematologic:

     • hemoglobin > 8 gm/dL
     • WBC > 2.5 x 109/L with an ANC > 1.5 x 109/L off G-CSF or GM-CSF for 10 days or Neulasta for 21 days
     • platelets > 100 x 109/L without transfusion
     • bone marrow cellularity of > 20% with <5% involvement with tumor
  2. Renal: GFR > 50 ml/min/1.73m2 or serum creatinine ≤ 2.5 x ULN for age
  3. Hepatic: no history of severe prior or ongoing chronic liver disease. Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase <5x upper limit of normal
  4. Cardiac: free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. The ejection fraction by gated cardiac blood flow scan (MUGA) or Echocardiogram must be >40%
  5. Pulmonary: no significant obstructive airways disease (FEV1 must be ≥ 50%) and must have acceptable diffusion capacity (corrected DLCO > 50% of predicted)
  6. Central Nervous System: Patients with a history of CNS involvement by lymphoma or with relapsed primary CNS lymphoma will be eligible for Cy/TBI arm. Patients with active CNS disease are eligible if they have completed a standard treatment for CNS lymphoma and have no evidence of progressive CNS disease at the time of enrollment

• Other Inclusion Criteria

  1. At least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas
  2. Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment
  3. Patients who are carriers of Hepatitis B will be included in this study
  4. Voluntary written consent

Exclusion Criteria:

• Pregnant or breastfeeding: Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
• Eligible for any higher priority transplant protocols
• Chemotherapy resistant disease
• Unrelated active infection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BEAM: NHL & HL; BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV	Drug: Etoposide; BEAM: 100 mg/m^2 IV over 2 hours BID on Days -5, -4, -3, -2 | CBV: 150 mg/m^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4; Other Names: VP-16; Drug: BCNU; BEAM & CBV: 300 mg/m^2 IV over over 2 hours on Day -6; Other Names: Carmustine; Drug: AraC; BEAM: 100 mg/m^2 IV over 1 hour BID on Days -5, -4, -3, -2; Other Names: Cytosar-U; Cytarabine; cytosine arabinoside; Depocyt; Drug: Melphalan; BEAM: 140 mg/m^2 IV over 20 minutes on Day -1; Other Names: Alkeran; Procedure: Peripheral blood stem cell transplantation; All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.; Other Names: PBSC; Biological: G-CSF; All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3; Other Names: filgrastim
Experimental: CBV: HL; Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients	Drug: Etoposide; BEAM: 100 mg/m^2 IV over 2 hours BID on Days -5, -4, -3, -2 | CBV: 150 mg/m^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4; Other Names: VP-16; Drug: BCNU; BEAM & CBV: 300 mg/m^2 IV over over 2 hours on Day -6; Other Names: Carmustine; Drug: Cyclophosphamide; CBV: 1.5 gm/M^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 | CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6; Other Names: Cytoxan
Experimental: CY/TBI; Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM	Procedure: Peripheral blood stem cell transplantation; All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.; Other Names: PBSC; Biological: G-CSF; All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3; Other Names: filgrastim; Drug: Cyclophosphamide; CBV: 1.5 gm/M^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 | CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6; Other Names: Cytoxan; Radiation: Total Body Irradiation; CY/TBI: 165 cGy bid on Day -4, -3, -2, -1; Other Names: TBI

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival Comparison	Compare progression-free survival (PFS) at 3 years post-transplant for patients who received who received a radiation free preparative regimen to the prior study MT2004-24 where NHL subjects received total body irradiation (TBI) as part of their preparative regimen.	3 years post transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	Incidence of survival	3 years post transplant
Treatment related mortality	Incidence of treatment related mortality	6 months post transplant
Treatment related mortality	Incidence of treatment related mortality	1 year post transplant
Secondary malignancies	Cumulative incidence of secondary malignancies	3 years post transplant
Neutrophil engraftment	Average days to neutrophil engraftment	Day +1 to engraftment
Platelet engraftment	Average days to platelet engraftment	Day +1 to engraftment

Collaborators and Investigators

• Sponsor: Masonic Cancer Center, University of Minnesota
• Investigators: Principal Investigator: Veronika Bachanova, MD, Masonic Cancer Center, University of Minnesota

Study record dates

Study Major Dates

• Study Start (Actual): April 20, 2017
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: April 19, 2017
• First Submitted That Met QC Criteria: April 19, 2017
• First Posted (Actual): April 24, 2017

Study Record Updates

• Last Update Posted (Estimated): November 4, 2025
• Last Update Submitted That Met QC Criteria: October 31, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: Follicular Lymphoma; Lymphoblastic Lymphoma; Mantle Cell Lymphoma; Diffuse Large B-Cell Lymphoma; Mature B-cell Lymphomas; Burkitt's/Burkitt's like; Mature T-Cell Lymphoma
• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma, B-Cell; Lymphoma; Leukemia, Lymphoid; Leukemia; Hemic and Lymphatic Diseases; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Hodgkin Disease; Lymphoma, T-Cell; Lymphoma, Mantle-Cell; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Investigative Techniques; Therapeutics; Surgical Procedures, Operative; Nucleic Acids, Nucleotides, and Nucleosides; Hydrocarbons; Hydrocarbons, Cyclic; Biological Factors; Carbohydrates; Podophyllotoxin; Tetrahydronaphthalenes; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Glucosides; Glycosides; Transplantation; Amides; Amino Acids; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Phosphoramides; Organophosphorus Compounds; Nucleosides; Intercellular Signaling Peptides and Proteins; Arabinonucleosides; Glycoproteins; Glycoconjugates; Radiotherapy; Cell Transplantation; Cell- and Tissue-Based Therapy; Biological Therapy; Phenylalanine; Amino Acids, Aromatic; Amino Acids, Cyclic; Colony-Stimulating Factors; Hematopoietic Cell Growth Factors; Cytokines; Stem Cell Transplantation; Nitrosourea Compounds; Urea; Nitroso Compounds; Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Carmustine; Melphalan; Etoposide; Granulocyte Colony-Stimulating Factor; Whole-Body Irradiation; Filgrastim; Peripheral Blood Stem Cell Transplantation
• Other Study ID Numbers: 2016LS132; MT2016-11C (Other Identifier: Masonic Cancer Center, University of Minnesota)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No